Nitazoxanide and IC41 Take on Interferon and Ribavirin
Share
Follow Us
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
— The companies are designing a treatment that combines Intercell’s investigational Hepatitis C vaccine, IC41, with Romark’s antiviral drug, nitazoxanide.
— A combination Phase II trial is expected to start in H1/2011.
— The trial will be sponsored by Romark. Intercell will provide the vaccine candidate IC41
.
VIENNA, Oct. 21 /PRNewswire/ — Intercell AG (VSE; “ICLL”) and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell’s investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark’s antiviral drug, nitazoxanide, during the first half of 2011.
Intercell’s vaccine candidate has demonstrated a sustained reduction of viral load in chronic Hepatitis C (CHC) patients in a Phase II proof-of-concept trial. Nitazoxanide is an oral therapy that targets host cell factors involved in HCV replication and is not associated with viral mutations conferring resistance. Nitazoxanide has been shown to induce sustained virologic response as monotherapy in some patients chronically infected with HCV.
Continue reading this entire article:
http://www.prnewswire.com/news-releases/intercell-and-romark-join-forces-in-combining-therapies-against-hepatitis-c-105416213.html
